BioNTech’s chief executive has said that the COVID-19 vaccine it developed with U.S. pharmaceutical group Pfizer is likely to be effective against the Indian variant of coronavirus. The German biotechnology company’s CEO, Ugur Sahin, said on Thursday in a meeting with the Turkish health minister that the vaccine’s effectiveness against the Indian variant was likely to be in the same range as for the South African variant, according to BioNTech. Sahin said that BioNTech and Pfizer’s COVID-19 vaccine has shown real-world effectiveness of 75% against the South African variant of the coronavirus, and that efficacy against the Indian variant might be in the same range.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
